Page last updated: 2024-11-07

3,5-diiodothyropropionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,5-diiodothyropropionic acid: a cardiotonic thyroid hormone analog [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,5-diiodothyropropionic acid : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)propanoic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxyphenyl group. An ionotropic analogue of L-thyroxine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160565
CHEMBL ID2348292
CHEBI ID134267
SCHEMBL ID1501771
MeSH IDM0219048

Synonyms (32)

Synonym
3,5-diiodothyropropionic acid
benzenepropanoic acid, 4-(4-hydroxyphenoxy)-3,5-diiodo-
3,5-ditpa
ditpa
dipta
3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
1158-10-7
3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propionic acid
CHEBI:134267
3,5-diiodo-4-(4-hydroxyphenoxy)hydrocinnamic acid
3,5-diiodothyropropanoic acid
bdbm50431457
1hto2x0sj9 ,
unii-1hto2x0sj9
dipro
AKOS005174585
3-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)propanoic acid
CHEMBL2348292 ,
SCHEMBL1501771
DTXSID8040939
J-003326
3 5-diiodothyropropionic acid
DB12629
HY-126236
diiodothyropropionic-acid
BB 0266169
CS-0100519
Q27252433
MS-29467
3-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)propanoicacid
EN300-2010041
Z2724205429
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proliferating cell nuclear antigenHomo sapiens (human)IC50 (µMol)32.00003.60004.95006.3000AID739861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIProliferating cell nuclear antigenHomo sapiens (human)
base-excision repair, gap-fillingProliferating cell nuclear antigenHomo sapiens (human)
mismatch repairProliferating cell nuclear antigenHomo sapiens (human)
heart developmentProliferating cell nuclear antigenHomo sapiens (human)
translesion synthesisProliferating cell nuclear antigenHomo sapiens (human)
epithelial cell differentiationProliferating cell nuclear antigenHomo sapiens (human)
replication fork processingProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of deoxyribonuclease activityProliferating cell nuclear antigenHomo sapiens (human)
response to estradiolProliferating cell nuclear antigenHomo sapiens (human)
cellular response to UVProliferating cell nuclear antigenHomo sapiens (human)
estrous cycleProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA repairProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA replicationProliferating cell nuclear antigenHomo sapiens (human)
response to cadmium ionProliferating cell nuclear antigenHomo sapiens (human)
cellular response to hydrogen peroxideProliferating cell nuclear antigenHomo sapiens (human)
cellular response to xenobiotic stimulusProliferating cell nuclear antigenHomo sapiens (human)
response to dexamethasoneProliferating cell nuclear antigenHomo sapiens (human)
liver regenerationProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA-directed DNA polymerase activityProliferating cell nuclear antigenHomo sapiens (human)
response to L-glutamateProliferating cell nuclear antigenHomo sapiens (human)
mitotic telomere maintenance via semi-conservative replicationProliferating cell nuclear antigenHomo sapiens (human)
leading strand elongationProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
purine-specific mismatch base pair DNA N-glycosylase activityProliferating cell nuclear antigenHomo sapiens (human)
chromatin bindingProliferating cell nuclear antigenHomo sapiens (human)
damaged DNA bindingProliferating cell nuclear antigenHomo sapiens (human)
protein bindingProliferating cell nuclear antigenHomo sapiens (human)
enzyme bindingProliferating cell nuclear antigenHomo sapiens (human)
nuclear estrogen receptor bindingProliferating cell nuclear antigenHomo sapiens (human)
receptor tyrosine kinase bindingProliferating cell nuclear antigenHomo sapiens (human)
dinucleotide insertion or deletion bindingProliferating cell nuclear antigenHomo sapiens (human)
MutLalpha complex bindingProliferating cell nuclear antigenHomo sapiens (human)
histone acetyltransferase bindingProliferating cell nuclear antigenHomo sapiens (human)
identical protein bindingProliferating cell nuclear antigenHomo sapiens (human)
protein-containing complex bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase processivity factor activityProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionProliferating cell nuclear antigenHomo sapiens (human)
male germ cell nucleusProliferating cell nuclear antigenHomo sapiens (human)
nucleusProliferating cell nuclear antigenHomo sapiens (human)
nuclear laminaProliferating cell nuclear antigenHomo sapiens (human)
nucleoplasmProliferating cell nuclear antigenHomo sapiens (human)
replication forkProliferating cell nuclear antigenHomo sapiens (human)
centrosomeProliferating cell nuclear antigenHomo sapiens (human)
nuclear bodyProliferating cell nuclear antigenHomo sapiens (human)
nuclear replication forkProliferating cell nuclear antigenHomo sapiens (human)
PCNA complexProliferating cell nuclear antigenHomo sapiens (human)
extracellular exosomeProliferating cell nuclear antigenHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexProliferating cell nuclear antigenHomo sapiens (human)
chromatinProliferating cell nuclear antigenHomo sapiens (human)
replisomeProliferating cell nuclear antigenHomo sapiens (human)
PCNA-p21 complexProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID739861Inhibition of human recombinant PCNA interaction with PIP box protein N-5-carboxyfluorescein-SAVLQKKITDYFHPKK after 30 mins by fluorescence polarization assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (18.18)18.2507
2000's19 (43.18)29.6817
2010's16 (36.36)24.3611
2020's1 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.80 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (8.51%)5.53%
Reviews8 (17.02%)6.00%
Case Studies2 (4.26%)4.05%
Observational0 (0.00%)0.25%
Other33 (70.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients With NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels [NCT00103519]Phase 286 participants (Actual)Interventional2004-12-31Terminated(stopped due to Study terminated for reasons unrelated to safety or efficacy.)
A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients [NCT00311987]Phase 1/Phase 260 participants (Anticipated)Interventional2006-04-30Terminated(stopped due to Curtailment of funding by sponsor)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]